deltatrials
Recruiting PHASE1 INTERVENTIONAL 2-arm NCT04771572

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

Sponsor: Newave Pharmaceutical Inc

Conditions Acute Lymphocytic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myelomonocytic Leukemia-2 Multiple Myeloma Myelodysplastic Neoplasm in Blast Phase Myelodysplastic/Myeloproliferative Neoplasm Myelofibrosis Myeodysplastic Syndrome Non Hodgkin Lymphoma Richter Transformation Small Lymphocytic Lymphoma T-cell-prolymphocytic Leukemia
Interventions LP-118
Updated 14 times since 2021 Last updated: Apr 23, 2024 Started: Aug 23, 2021 Primary completion: Oct 1, 2025 Completion: Oct 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Lymphocytic Leukemia and Acute Myeloid Leukemia and is currently actively recruiting participants. Newave Pharmaceutical Inc leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~May 2024 · 13 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 20 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  3. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. Apr 2023 — May 2024 [monthly]

    Recruiting PHASE1

  5. Nov 2022 — Apr 2023 [monthly]

    Recruiting PHASE1

▶ Show 9 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  2. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  3. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  4. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  5. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  6. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  7. May 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1

  8. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

  9. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Newave Pharmaceutical Inc
Data source: Newave Pharmaceutical Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations